In HER2- and ER-positive breast cancer cell lines, AXL promotes resistance to lapatinib and trastuzumab; for example, BT474 cells resistant to lapatinib show higher AXL levels as compared to the same control cells. Here, ERBB2 is linked to breast cancer.